Nabil F Saba, MD, FACP, Emory University

Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.

Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.

Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.

A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.